MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./270/0.1/20.09.24 Stock

Warrant

DE000ME9GR22

Real-time Bid/Ask 08:59:07 2024-06-14 EDT
0.16 EUR / 0.25 EUR +7.33% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./270/0.1/20.09.24
Current month+64.66%
1 month-1.04%
Date Price Change
24-06-14 0.16 -16.23%
24-06-13 0.191 +15.06%
24-06-12 0.166 -8.29%
24-06-11 0.181 -6.70%
24-06-10 0.194 -11.82%

Delayed Quote Börse Stuttgart

Last update June 14, 2024 at 07:22 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN ME9GR2
ISINDE000ME9GR22
Date issued 2024-03-01
Strike 270 $
Maturity 2024-09-20 (98 Days)
Parity 10 : 1
Emission price 0.5
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.66
Lowest since issue 0.065
Spread 0.09
Spread %36.00%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
232 USD
Average target price
278.7 USD
Spread / Average Target
+20.14%
Consensus